Pfizer In Talks To Buy Drugmaker For $5 Billion: Report
NDTV
Pfizer, one of the top makers of Covid-19 vaccines, hopes to conclude talks with Global Blood Therapeutics within days, the Wall Street Journal said Friday, citing people close to the negotiations.
American drugmaker Pfizer is close to a deal to purchase Global Blood Therapeutics, which manufactures a recently approved drug against sickle-cell anemia, for $5 billion, the Wall Street Journal has reported.
Pfizer, one of the top makers of Covid-19 vaccines, hopes to conclude talks with GBT within days, the newspaper said Friday, citing people close to the negotiations.
But it said other takeover candidates remain in the running.
GBT's sickle-cell treatment, marketed as Oxbryta, was authorized for those over 12 years old in 2019 but gained federal approval in December for children aged four to 11. The blood disorder affects millions.
